Clinical Evidence on Apatinib in Treating Chemotherapy-Refractory Metastatic Esophageal Squamous Cell Carcinoma

Download Citation in txt Download Citation in bib Download Citation in ris

Author Info

Leiming Guo Chengliang Yang Chunyu He Ke Li Lei Qiao Shuning Xu Xiaoyuan Wu Ying Liu

Corresponding Author

Ying Liu
Department of Medical Oncology, Zhengzhou University Affiliated Cancer Hospital, Henan Cancer Hospital, Zhengzhou, Henan, China

A B S T R A C T

Majority Chinese esophageal cancer patients have squamous cell carcinoma (ESCC) and with metastasis at initial diagnosis. Treatment for metastatic ESCC where first-line chemotherapy failed is an unmet medical need. Targeting human epidermal growth factor receptor 2 (HER2) and vascular endothelial growth factor receptor 2 (KDR) have been approved to be effective for esophageal adenocarcinoma (EAC). We explored the clinical relevance of these molecular signaling in ESCC cohorts and collected clinical evidence on applying apatinib, a Chinese FDA-approved KDR inhibitor for late-stage gastric carcinoma, in 26 patients with chemotherapy-refractory metastatic ESCC. The clinical response rate and disease control rate of these patients to apatinib 500mg once daily regimen was 12% and 60%, respectively. The patients’ median progression-free survival time (PFS) was 3.2 months (95% CI, 2.23-4.17 months) and overall survival time (OS) was 5.3 months (95% CI, 4.46-6.14 months). The most common grade 3-4 treatment-related adverse events included leukopenia (7.7%) and anemia (7.7%). No drug-related death occurred. In conclusion, apatinib has favorable activity and acceptable safety, and could be a new treatment option for patients with chemotherapy refractory metastatic ESCC.

Article Info

Article Type

Research Article

Publication history

Received: Wed 11, Mar 2020
Accepted: Mon 30, Mar 2020
Published: Wed 08, Apr 2020

Copyright

© 2023 Ying Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Hosting by Science Repository.
DOI: 10.31487/j.COR.2020.03.08